Retinoic acid

Primary Application
Imprint
For what
Blood and Cardiovascular
Immune and Lymphatic
Integumentary
Mitochondrial and Energy Production
Source
Allopathy
For whom
People

All Trans Retinoic Acid (ATRA) is FDA approved in the treatment of promyelocytic leukemia. ATRA is a strong differentiating agent. As such, ATRA has potential as a therapy in a number of cancers, especially in the context of IC medicines. ATRA binds to retinoic acid receptors, and subsequently activates DNA transcription activity to move immature (e.g. malignant) cells toward normal maturation. Consider the use of ATRA in cases of cancer and precancerous lesions, including polyps, actinic keratosis, and others.


Retinoic acid
Replies
Show modal
Similar ICs
Imprint Temozolomide is the most widely used chemotherapeutic agent in the treatment of the most common form of brain cancer, called glioblastoma (GBM). Te...
Imprint Methylene blue is a dye that was first developed to stain and inactivate certain microbes. It was also one of the first chemotherapeutic medication...
Imprint This compound belongs to the group of benzimidazole carbamates, drugs widely used in human and veterinary medicine against parasitic worms. The mol...
Show modal